PLCG2 rs72821788: What Your Genotype Means
The rs72821788 variant is a missense alteration located within the PLCG2 gene, also widely cataloged in literature under the identifier rs72824905. It produces the amino acid substitution p.Pro522Arg, which leads to a slight functional gain in microglial signaling. Epidemiological and genetic association studies have linked this variant to a significantly reduced risk of Alzheimer's disease and other forms of neurodegeneration.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | This is the baseline, standard genotype found in more than 98% of the global population. It is not associated with reduced or elevated risk compared to the general population average. | Informational |
| CG | Carrying one copy of the protective G allele is associated with approximately a 30% lower statistical risk of late-onset Alzheimer's disease and related dementias. It reflects enhanced microglial clearance mechanisms in neurodegenerative research models. | Favorable |
| GG | Carrying two copies of the protective allele is exceptionally rare across all global populations. Studies suggest a continued or amplified reduction in neurodegenerative risk, though very small sample sizes limit precise statistical estimation. | Favorable |
Genetic Architecture and Variant Identity
The PLCG2 variant rs72821788 (often referenced interchangeably with rs72824905 in academic publications) is a single nucleotide polymorphism located on chromosome 16. It represents a single base transition (c.1565C>G) resulting in the missense substitution of proline with arginine at position 522 (p.Pro522Arg) in the regulatory region of the enzyme. Phospholipase C gamma 2 (PLCγ2) acts as a pivotal signal transducer in immune cells, especially brain-resident microglia and peripheral macrophages. The p.Pro522Arg change is a mild hypermorphic or gain-of-function variation that modifies enzyme activity without causing the uncontrolled immune signaling seen in severe autoimmune syndromes caused by rarer mutations in the same gene. Databases such as ClinVar and dbSNP index this locus primarily for its observed associations with neuroprotection and altered inflammatory biology.
Biological Role in Microglial Function
In the central nervous system, PLCγ2 serves as an obligate downstream signaling node for surface receptors, including TREM2 (Triggering Receptor Expressed on Myeloid Cells 2). When microglial receptors encounter pathogen- or damage-associated molecular patterns, such as amyloid-beta aggregates, PLCγ2 hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate second messengers that mobilize intracellular calcium. Cellular and rodent studies indicate that the p.Pro522Arg substitution modestly boosts this enzymatic turnover. Consequently, microglia carrying the variant demonstrate improved cell survival, more efficient phagocytosis, and enhanced clearance of neurotoxic proteins. By promoting a sustained and beneficial myeloid response rather than a dysfunctional pro-inflammatory state, the altered protein helps maintain neurovascular integrity and delays neurodegenerative processes.
Current Research and Clinical Evidence
Large-scale genome-wide association studies (GWAS) and meta-analyses comprising tens of thousands of participants have demonstrated that the minor allele is associated with a 30% to 35% reduction in the odds of developing late-onset Alzheimer's disease (odds ratio approximately 0.68). Beyond Alzheimer's, observational cohorts have reported that the protective effect extends across other neurodegenerative proteinopathies, notably frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB). Furthermore, several cohorts investigating extreme human longevity have noted an enrichment of the minor allele in cognitively healthy centenarians. Because of the relatively low minor allele frequency in global populations, statistical evidence remains categorized as limited to moderate under standard clinical curation frameworks like ClinGen, although replication across multiple independent neurodegenerative cohorts has been consistent.
Ancestry and Population Distribution
The protective allele is relatively rare worldwide, with pronounced variation across different ancestral groups. According to population databases such as gnomAD, the minor allele frequency is estimated between 0.5% and 1.0% in populations of European ancestry. In contrast, it is observed at substantially lower frequencies or is entirely absent in individuals of East Asian, African, and admixed American ancestries. Because of this rarity, the overwhelming majority of people carry two copies of the common baseline allele. The homozygous protective genotype is exceptionally rare in the general population. The limited representation in non-European ancestries also emphasizes that conclusions drawn from current published cohorts cannot yet be universally applied across all global backgrounds.
Interpretation and Practical Considerations
Genetic tests reporting a carrier status for rs72821788 provide statistical context rather than a medical diagnosis. Carrying the protective allele significantly reduces the relative statistical risk of late-onset Alzheimer's and frontotemporal dementia, but it does not confer complete immunity against cognitive decline. Conversely, having the typical baseline genotype does not mean a person is guaranteed to develop dementia, as overall risk is shaped by a complex interplay of age, lifestyle, cardiovascular health, and dozens of other genetic loci such as APOE. Genetic data of this type should not be used to alter medical treatments or diagnostic pathways without professional clinical oversight, nor does it warrant specialized screening outside established geriatric care guidelines.
How common is this variant?
The minor protective allele has a frequency of approximately 0.5% to 1.0% in individuals of European ancestry and is extremely rare or undetectable in African, East Asian, and other ancestral populations.
Frequently asked questions
Does having the PLCG2 protective allele mean I cannot develop Alzheimer's disease?
No. While the variant is associated with an approximate 30% reduction in relative risk, it does not guarantee immunity. Neurodegenerative diseases are multifactorial conditions influenced by many genetic variants, age, cardiovascular health, and lifestyle factors.
Why is this variant also referred to as rs72824905 in scientific papers?
Genetic databases occasionally assign different reference numbers (rsIDs) to the same specific genomic coordinate during updates to the reference human genome. In the scientific literature, both rs72821788 and rs72824905 refer to the same p.Pro522Arg alteration in the PLCG2 gene.
Can this genetic variant help protect against other brain diseases?
Studies suggest that the protective effect is not restricted solely to Alzheimer's disease. Research has identified statistically significant risk reductions for frontotemporal dementia and dementia with Lewy bodies, as well as an association with longevity in healthy centenarians.
Should I change any medications based on my PLCG2 genotype?
No. There are currently no approved therapies or dosing protocols calibrated to PLCG2 genotype status. Any questions or adjustments regarding medications and neurological health should always be reviewed directly with a qualified healthcare provider.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs72821788?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29